Glucagon-like Peptide 1 Receptor Agonists Outperform Basal Insulin in Cardiovascular and Renal Outcomes for Type 2 Diabetes Mellitus: a Retrospective Cohort Study

Overview

Journal Acta Diabetol

Date 2025 Jan 15

PMID 39812791

Authors

Tien-Hsing Chen

Chin-Ju Tseng

Yan-Rong Li

Yuan Lin

Dong-Yi Chen

Ning-I Yang

Te-Hsiung Wang

Ming-Jui Hung

Ming-Lung Tsai

Affiliations

Soon will be listed here.

Abstract

Purpose: Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and basal insulin are currently used in the treatment of type 2 diabetes mellitus (T2DM) as long-acting injectables. In this study, we aimed to compare the cardiovascular (CV) and renal outcomes of GLP-1 RAs and basal insulin treatment in patients with T2DM.

Method: We conducted a propensity score-matched cohort study of patients from Chang Gung Memorial Hospital institutions between 2013 and 2021. A diverse patient base from multiple centers was enrolled to enhance the applicability of the findings, including patients with T2DM who were prescribed either GLP-1 RAs or basal insulin.

Results: Over a mean follow-up period of 2.2 years, 10,839 patients were collected (mean age = 54.3 years; 54.2% men). Among the propensity score-matched patients, 45 (2.23%) in the GLP-1 RA group (2,854 patients) and 72 (3.56%) in the basal insulin group (7,985 patients) experienced 3-point major adverse cardiovascular events (3P-MACEs; hazard ratio [HR] 0.68, 95% CI 0.47-0.99, P =.44). Additionally, composite renal outcomes were observed in 237 (11.7%) patients in the GLP-1 RA group and 360 (17.8%) in the basal insulin group (HR 0.69, 95% CI 0.59-0.81, P <.001).

Conclusions: In patients with T2DM, GLP-1 RAs were associated with more favorable cardiovascular and renal outcomes than basal insulin, suggesting that GLP-1 RA treatment may be a preferable option for managing T2DM with a lower risk of CV and renal complications.

References

Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A . IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138:271-281. DOI: 10.1016/j.diabres.2018.02.023. View

Einarson T, Acs A, Ludwig C, Panton U . Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018; 17(1):83. PMC: 5994068. DOI: 10.1186/s12933-018-0728-6. View

Gheith O, Farouk N, Nampoory N, Halim M, Al-Otaibi T . Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2017; 5(1):49-56. PMC: 5297507. View

Meier J . GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012; 8(12):728-42. DOI: 10.1038/nrendo.2012.140. View

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

Holman R, Bethel M, Mentz R, Thompson V, Lokhnygina Y, Buse J . Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13):1228-1239. PMC: 9792409. DOI: 10.1056/NEJMoa1612917. View

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3. View

Palmer S, Tendal B, Mustafa R, Vandvik P, Li S, Hao Q . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021; 372:m4573. PMC: 7804890. DOI: 10.1136/bmj.m4573. View

10.

Kosiborod M, Petrie M, Borlaug B, Butler J, Davies M, Hovingh G . Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024; 390(15):1394-1407. DOI: 10.1056/NEJMoa2313917. View

11.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Furtado R . Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019; 139(17):2022-2031. DOI: 10.1161/CIRCULATIONAHA.118.038868. View

12.

Lin Y, Wang T, Tsai M, Wu V, Tseng C, Lin M . The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol. 2023; 22(1):60. PMC: 10024371. DOI: 10.1186/s12933-023-01793-9. View

13.

Perkovic V, Tuttle K, Rossing P, Mahaffey K, Mann J, Bakris G . Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024; 391(2):109-121. DOI: 10.1056/NEJMoa2403347. View

14.

ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S140-S157. PMC: 9810476. DOI: 10.2337/dc23-S009. View

15.

Giorgino F, Benroubi M, Sun J, Zimmermann A, Pechtner V . Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. 2015; 38(12):2241-9. DOI: 10.2337/dc14-1625. View

16.

Aroda V, Bain S, Cariou B, Piletic M, Rose L, Axelsen M . Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group,.... Lancet Diabetes Endocrinol. 2017; 5(5):355-366. DOI: 10.1016/S2213-8587(17)30085-2. View

17.

Eng C, Kramer C, Zinman B, Retnakaran R . Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014; 384(9961):2228-34. DOI: 10.1016/S0140-6736(14)61335-0. View

18.

Lingvay I, Perez Manghi F, Garcia-Hernandez P, Norwood P, Lehmann L, Tarp-Johansen M . Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. JAMA. 2016; 315(9):898-907. DOI: 10.1001/jama.2016.1252. View

19.

Evans M, Kuodi P, Akunna C, McCreedy N, Donsmark M, Ren H . Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis. Diab Vasc Dis Res. 2023; 20(6):14791641231221740. PMC: 10734357. DOI: 10.1177/14791641231221740. View

20.

Shao S, Chan Y, Kao Yang Y, Lin S, Hung M, Chien R . The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019; 28(5):593-600. DOI: 10.1002/pds.4713. View